middle.news
Why Is Health Canada Delaying SCENESSE® Approval for Rare EPP Treatment?
1:11pm on Thursday 16th of October, 2025 AEDT
•
Healthcare
Read Story
Why Is Health Canada Delaying SCENESSE® Approval for Rare EPP Treatment?
1:11pm on Thursday 16th of October, 2025 AEDT
Key Points
Health Canada delays SCENESSE® approval, review extended into 2026
Additional information requested despite prior approvals in US, Europe, Australia
SCENESSE® remains accessible in Canada through Special Access Program
Treatment targets rare metabolic disorder erythropoietic protoporphyria (EPP)
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE